Answers are grounded in this paper and cite their sources.
This study evaluates the efficacy of imiquimod liposome gel (IMQ-Lips gel) to prevent and treat hypertrophic scars (HS). On the basis of an orthogonal L9 (34) design, IMQ-Lips formulations were optimized using the film dispersion-pH gradient method. The optimal parameters were phospholipid–cholesterol (3 : 1), lipid-to-drug ratio (8 : 1), and a vitamin E of 5 mg. The in vitro transdermal experiment and rabbit HS model were used to evaluate the pharmacodynamics in vitro and in vivo. IMQ-Lips has good physical and chemical properties, with an encapsulation rate of 81.2% ± 1.9%, an average diameter of (347 ± 21) nm, and a zeta potential of (–12.19 ± 1.7) mV. In vitro transdermal penetration tests showed that IMQ-Lips gel enhanced skin retention and reduced transdermal delivery compared with IMQ gel. The rabbit HS model further revealed that IMQ-Lips gel treatment reduced scar formation by inhibiting overproliferation of fibroblasts and reducing interleukin-4 levels. Taken together, these data suggest that IMQ-Lips gel represents a potential therapeutic approach for HS treatment.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: